Pazzaglia P J, George M S, Post R M, Rubinow D R, Davis C L
Biological Psychiatry Branch, National Institute of Mental Health, Bethesda, MD 20892-1272, USA.
Neuropsychopharmacology. 1995 Aug;13(1):75-83. doi: 10.1016/0893-133X(95)00024-8.
Preliminary evidence suggests that nimodipine, an L-type calcium channel blocker, is effective in treating some patients with rapidly cycling affective disorders and some phases of Alzheimer's disease, i.e., two syndromes associated with transient or permanent reductions in cerebrospinal fluid (CSF) somatostatin, respectively. CSF somatostatin (SRIF) was measured in 14 affectively ill patients while they were medication-free and during chronic nimodipine treatment. CSF somatostatin significantly increased in patients during active nimodipine treatment compared with ones in the medication-free state. The current findings raise the possibility that nimodipine-induced increases in CSF somatostatin could potentially contribute to its spectrum of efficacy on neuropsychiatric disorders associated with cognitive or affective impairment. Further clinical and preclinical studies are indicated to elucidate the potential mechanisms involved in the elevation of CSF SRIF, whether it is reflected in regional changes in brain, and its possible relevance to nimodipine's clinical actions.
初步证据表明，L型钙通道阻滞剂尼莫地平在治疗一些快速循环型情感障碍患者和阿尔茨海默病的某些阶段有效，这两种综合征分别与脑脊液（CSF）生长抑素的短暂或永久性减少有关。在14名情感障碍患者未服药时以及慢性尼莫地平治疗期间测量了脑脊液生长抑素。与未服药状态相比，在尼莫地平积极治疗期间患者脑脊液生长抑素显著增加。目前的研究结果提出了一种可能性，即尼莫地平引起的脑脊液生长抑素增加可能有助于其对与认知或情感障碍相关的神经精神疾病的疗效范围。需要进一步的临床和临床前研究来阐明脑脊液生长抑素升高所涉及的潜在机制，它是否反映在大脑的区域变化中，以及它与尼莫地平临床作用的可能相关性。
